These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24176400)

  • 1. Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases.
    Deau E; Loidreau Y; Marchand P; Nourrisson MR; Loaëc N; Meijer L; Levacher V; Besson T
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6784-8. PubMed ID: 24176400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and molecular modelling studies of 8-arylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amines as multitarget Ser/Thr kinases inhibitors.
    Loidreau Y; Deau E; Marchand P; Nourrisson MR; Logé C; Coadou G; Loaëc N; Meijer L; Besson T
    Eur J Med Chem; 2015 Mar; 92():124-34. PubMed ID: 25549552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases.
    Loidreau Y; Marchand P; Dubouilh-Benard C; Nourrisson MR; Duflos M; Loaëc N; Meijer L; Besson T
    Eur J Med Chem; 2013 Jan; 59():283-95. PubMed ID: 23237976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors.
    Loidreau Y; Marchand P; Dubouilh-Benard C; Nourrisson MR; Duflos M; Lozach O; Loaëc N; Meijer L; Besson T
    Eur J Med Chem; 2012 Dec; 58():171-83. PubMed ID: 23124214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
    Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
    Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting NF-κB-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures.
    Li K; McGee LR; Fisher B; Sudom A; Liu J; Rubenstein SM; Anwer MK; Cushing TD; Shin Y; Ayres M; Lee F; Eksterowicz J; Faulder P; Waszkowycz B; Plotnikova O; Farrelly E; Xiao SH; Chen G; Wang Z
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1238-44. PubMed ID: 23374866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of novel hetero ring fused pyridine derivatives; Their anticancer activity, CoMFA and CoMSIA studies.
    Santhosh Kumar G; Poornachandra Y; Kumar Gunda S; Ratnakar Reddy K; Mohmed J; Shaik K; Ganesh Kumar C; Narsaiah B
    Bioorg Med Chem Lett; 2018 Jul; 28(13):2328-2337. PubMed ID: 29798826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors.
    Han J; Kaspersen SJ; Nervik S; Nørsett KG; Sundby E; Hoff BH
    Eur J Med Chem; 2016 Aug; 119():278-99. PubMed ID: 27235841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.
    Esvan YJ; Zeinyeh W; Boibessot T; Nauton L; Théry V; Knapp S; Chaikuad A; Loaëc N; Meijer L; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2016 Aug; 118():170-7. PubMed ID: 27128181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
    Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
    Anderson K; Chen Y; Chen Z; Dominique R; Glenn K; He Y; Janson C; Luk KC; Lukacs C; Polonskaia A; Qiao Q; Railkar A; Rossman P; Sun H; Xiang Q; Vilenchik M; Wovkulich P; Zhang X
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6610-5. PubMed ID: 24239188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Divergent synthesis of kinase inhibitor derivatives, leading to discovery of selective Gck inhibitors.
    Matsumaru T; Inai M; Ishigami K; Iwamatsu T; Maita H; Otsuguro S; Nomura T; Matsuda A; Ichikawa S; Sakaitani M; Shuto S; Maenaka K; Kan T
    Bioorg Med Chem Lett; 2017 May; 27(10):2144-2147. PubMed ID: 28385506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of 2-anilino-4-substituted-7H-pyrrolopyrimidines as PDK1 inhibitors.
    O'Brien NJ; Brzozowski M; Buskes MJ; Deady LW; Abbott BM
    Bioorg Med Chem; 2014 Aug; 22(15):3879-86. PubMed ID: 25012568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel tricyclic pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine derivatives as VEGFR-2 inhibitors.
    Abdel Aziz YM; Said MM; El Shihawy HA; Abouzid KA
    Bioorg Chem; 2015 Jun; 60():1-12. PubMed ID: 25899678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinase inhibitions in pyrido[4,3-h] and [3,4-g]quinazolines: Synthesis, SAR and molecular modeling studies.
    Zeinyeh W; Esvan YJ; Josselin B; Baratte B; Bach S; Nauton L; Théry V; Ruchaud S; Anizon F; Giraud F; Moreau P
    Bioorg Med Chem; 2019 May; 27(10):2083-2089. PubMed ID: 30967303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents.
    Kassis P; Brzeszcz J; Bénéteau V; Lozach O; Meijer L; Le Guével R; Guillouzo C; Lewiński K; Bourg S; Colliandre L; Routier S; Mérour JY
    Eur J Med Chem; 2011 Nov; 46(11):5416-34. PubMed ID: 21944287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
    Tazarki H; Zeinyeh W; Esvan YJ; Knapp S; Chatterjee D; Schröder M; Joerger AC; Khiari J; Josselin B; Baratte B; Bach S; Ruchaud S; Anizon F; Giraud F; Moreau P
    Eur J Med Chem; 2019 Mar; 166():304-317. PubMed ID: 30731399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Xin M; Zhao X; Huang W; Jin Q; Wu G; Wang Y; Tang F; Xiang H
    Bioorg Med Chem; 2015 Oct; 23(19):6250-7. PubMed ID: 26344595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives.
    Zeinyeh W; Esvan YJ; Nauton L; Loaëc N; Meijer L; Théry V; Anizon F; Giraud F; Moreau P
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4327-9. PubMed ID: 27469128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.